Form 8-K - Current report:
SEC Accession No. 0001013762-25-004236
Filing Date
2025-03-28
Accepted
2025-03-28 17:09:55
Documents
13
Period of Report
2025-03-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0236055-8k_nektar.htm   iXBRL 8-K 29802
  Complete submission text file 0001013762-25-004236.txt   202392

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE nktr-20250328.xsd EX-101.SCH 3008
3 XBRL LABEL FILE nktr-20250328_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE nktr-20250328_pre.xml EX-101.PRE 22354
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0236055-8k_nektar_htm.xml XML 3575
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 25787546
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)